CAJ | 학술논문

目的探讨丙型肝炎抗体阳性供肝应用于丙型肝炎相关性肝病肝移植的效果及受者预后.方法自2007年1月至2013年6月,单中心157例丙型肝炎相关性肝病肝移植受者,其中19例接受了丙型肝炎阳性供肝,为研究组;138例接受了丙型肝炎阴性供肝,为对照组.比较两组术后受者存活率、丙型肝炎复发率、复发时间及复发的严重程度.结果研究组肝移植术后1年和5年受者存活率分别为89.5％和67.0％,对照组肝移植术后1年和5年受者生存率分别为82.4％和69.4％.研究组受者术后17例(89.5％)丙型肝炎复发,其中4例(21.0％)进展为重症肝炎;对照组丙型肝炎复发117例(84.8％),其中24例(17.4％)进展为重症肝炎;两组复发率和进展为重症肝炎者百分率相比较,差异无统计学意义(P＞0.05).结论对于接受丙型肝炎阳性和阴性供肝肝移植的受者,其存活率、术后丙型肝炎复发率、重症肝炎发生率之间的差异无统计学意义.对于丙型肝炎相关性肝病受者,对供肝质量进行认真评估后可以考虑使用丙型肝炎抗体阳性供肝.
목적 탐토병형간염항체양성공간응용우병형간염상관성간병간이식적효과급수자예후.방법 자2007년1월지2013년6월,단중심157례병형간염상관성간병간이식수자,기중19례접수료병형간염양성공간,위연구조;138례접수료병형간염음성공간,위대조조.비교량조술후수자존활솔、병형간염복발솔、복발시간급복발적엄중정도.결과 연구조간이식술후1년화5년수자존활솔분별위89.5％화67.0％,대조조간이식술후1년화5년수자생존솔분별위82.4％화69.4％.연구조수자술후17례(89.5％)병형간염복발,기중4례(21.0％)진전위중증간염;대조조병형간염복발117례(84.8％),기중24례(17.4％)진전위중증간염;량조복발솔화진전위중증간염자백분솔상비교,차이무통계학의의(P＞0.05).결론 대우접수병형간염양성화음성공간간이식적수자,기존활솔、술후병형간염복발솔、중증간염발생솔지간적차이무통계학의의.대우병형간염상관성간병수자,대공간질량진행인진평고후가이고필사용병형간염항체양성공간.
Objective To discuss the outcomes and effect of liver transplantation from anti-hepatitis C virus-positive donors to hepatitis C-related liver disease.Method From January 2007 to June 2013,we performed 157 liver transplants to treat end-stage liver disease secondary to hepatitis C virus (HCV) infection.Nineteen patients received livers from HCV-positive donors as study group.138 HCV-positive patients underwent OLT during the same period with organs from HCV-negative donors as control group.The recipient and graft survivals but also frequency,timing and severity of hepatitis recurrence were analyzed.Result The 1-and 5-year cumulative survival rate in test group was 89.5％ and 67.0％,and that in control group was 82.4％ and 69.4％,respectively.In test group,HCR recurred in 17 cases (89.5％) after liver transplantation,and 4 (21.1％) cases progressed to severe hepatitis.In control group,HCR recurred in 117 cases (84.8％),and 24 (17.4％) cases progressed to severe hepatitis.No statistically significant difference in the recurrence and progression to severe hepatitis was found between two groups.Conclusion For the recipients of hepatitis C-related liver diseases,grafts from HCV-positive donors can be used after careful assessment.